Making Pain Relief Affordable – Or Abuse Cheaper?
This article was originally published in RPM Report
Executive Summary
There are many arguments against generics of opioids, especially if you’re Purdue Pharma. Here’s a new one: they’re lower the cost for abusers.
You may also be interested in...
DEA Delays in Scheduling Are Offsetting FDA’s Improved Decision Making
FDA is showing a renewed commitment to meeting review deadlines for new molecular entities, but that is not translating into earlier commercial availability for all NMEs. Some products also need a controlled substance scheduling decision from the Drug Enforcement Administration; those actions have become a new regulatory purgatory that can be painful and frustrating.
Not So Fast: Trump Team Paints US FDA Review Times As Too Slow
New ‘statement of policy’ directs US FDA to publish charts of its approval timeliness – using an outdated 180-day benchmark to make its approval speed look worse.
US FDA ‘Bruised’ But Not Broken: Former Commissioners See Agency Intact Amid Transition
Three former commissioners believe FDA has come through the Trump administration relatively unscathed when compared to the reputational damage suffered by other government agencies. Will the Biden team agree?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: